EN DE
Watch Jazz Pharmaceuticals PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jazz Pharmaceuticals PLC (JAZZ) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Jazz Pharmaceuticals PLC stock $368, price $227, upside +61.7%, quality 53 out of 100. Rating: strongly undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Ireland

JP Jazz Pharmaceuticals PLC logo Some data Nov 3, 2026

Jazz Pharmaceuticals PLC

JAZZ · US
Meets all rules: undervalued, solid quality, uptrend

The stock costs 38% less than our calculation considers fair.

Fair value $367.54 · Strongly undervalued (38%)
Highly profitable · 20.5% net margin (TTM)
Generates free cash flow
Ranks above peers (11/13)
Revenue last quarter +16% vs. a year ago.
Quality 53/100
Mixed Growth (revenue 5y +12.5 %/yr in USD)
Moderate debt
Wide moat 67/100 · thin data
Neutral coverage
Insiders sold $32.8M (6M)
Some data
⚠ Dilution

Risks from the AI analysis

🚩Generics could cut oxybate sales🚩Lumryz could take narcolepsy share
Watch Jazz Pharmaceuticals PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$261.62 $97.78 Fair Value $367.54 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range $97.78 – $261.62 · fair‑value band $178.25 – $656.64 · the $227.32 price screens below the $367.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Jazz Pharmaceuticals in your weekly email

Every Wednesday you see whether Jazz Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

Show moreShow less

The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.

It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.

In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials.

Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials.

The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Stock analysis

Jazz Pharmaceuticals PLC (JAZZ) currently trades at $227.32, while our model-based Fair Value estimate is $367.54, implying the stock looks roughly 38% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $319.07 per share, and 9 of the 13 models we run sit above the $227.32 price.

Bear case: the Earnings-Based group reads lowest at $77.79, and 4 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $178.25 (bear) to $656.64 (bull), the price of $227.32 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jazz Pharmaceuticals PLC reported revenue of $4.3B in FY2025 versus $3.1B in FY2021, a compound +8.4%/yr. Reported net income was −$356M in FY2025.

Key figures

Market cap $15.8B Large · P/E ratio 67.3 · P/S ratio 3.03 · EPS (TTM) $3.38 · Net margin −8.3% · Return on equity 22.1% · Return on assets (EBIT) 2.7% · Operating margin 26.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 67 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 13% below its 52-week high and 73% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at 62%, JAZZ screens cheaper than that median.

Fair Value models

Bear $178.25 Fair Value $367.54 Bull $656.64
Price $227.32 · Upside +61.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.87 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $58.52 $77.79 $95.17 74
FCF DCF $297.17 $587.08 $1,425 73
5Y EBITDA Exit $209.70 $432.40 $772.52 72
All 13 models by family
DCF Models
FCF DCF $297.17 $587.08 $1,425 73
Owner Earnings $78.05 $238.08 $591.73 67
5Y Revenue Exit $122.97 $239.72 $425.21 69
5Y EBITDA Exit $209.70 $432.40 $772.52 72
10Y Revenue Exit $167.20 $319.07 $521.54 65
10Y EBITDA Exit $234.40 $482.54 $910.87 65
Earnings-Based
EPV $58.52 $77.79 $95.17 74
Multiples
EV/EBIT $78.64 $125.56 $172.48 64
EV/EBITDA $166.43 $242.61 $318.79 67
EV/Revenue $38.35 $81.40 $124.46 51
Growth DCF
Growth DCF $285.86 $682.48 $1,490 72
Rev-Margin DCF $122.97 $245.97 $423.74 70
Economic Profit
ROIC Compounder $58.52 $95.67 $146.18 70

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 17
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 35
Debt, balance sheet and risk of trouble
Investment 76
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 58
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 87
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 8 officers or directors sold shares worth $32.8M and none bought.

  • SaleRenee D GalaPresident & CEO, Director3× since Sep 8, 2026: 5,000 shares, avg. $236.85$1.2MNov 3, 202610b5-1 plan
  • SaleBruce C CozaddDirector11× since Nov 18, 2025: 149,500 shares, avg. $194.45$29.1MNov 2, 2026
  • SaleNeena M PatilEVP & Chief Legal Officer4× since Feb 26, 2026: 59,192 shares, avg. $194.29$11.5MSep 10, 2026
  • SaleRobert IannoneEVP, Global Head of R&D & CMO2× since Nov 17, 2025: 84,080 shares, avg. $242.77$20.4MAug 27, 202610b5-1 plan
  • SaleMark Douglas SmithDirector1,157 shares at $230.55$266,746Jun 15, 202610b5-1 plan
  • SaleSamantha PearceEVP, Chief Commercial Officer6,907 shares at $235.41$1.6MMay 28, 2026
  • SaleRick E WinninghamDirector2× since Nov 18, 2025: 8,241 shares, avg. $201.05$1.7MMay 22, 2026
  • SaleHeather Ann McSharryDirector2× since Nov 20, 2025: 5,415 shares, avg. $201.13$1.1MMay 22, 2026
  • SalePatricia CarrSVP, Chief Accounting Officer4× since Nov 18, 2025: 13,636 shares, avg. $180.26$2.5MMar 9, 2026
  • SaleNorbert G RiedelDirector3,415 shares at $192.00$655,680Feb 27, 2026

Plus 1 more entries from the last 12 months.

Plus 35 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 88/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Start year 2020 (pandemic). Over 10 years: +12.4% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
24.6% (2019) → 17.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −0.9% a year for the price and +3.8% for the forecasts.
Forecast 2026 (sales)+11.0%
Forecast 2027 (sales)+5.9%
Projected 2028 (sales)+5.4%
Projected 2029 (sales)+4.9%
Projected 2030 (sales)+4.4%

Watch JAZZ, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Note from the team Oct 11, 2026
AI conclusion: Jazz shows strength through commercial execution and revenue growth from rare-disease acquisitions but is held back by negative earnings and high debt.
Main risk: Generic versions of Xywav and Xyrem from filers such as Amneal and Lupin could enter the market after patent settlements or challenges and reduce prices and margins on Jazz's core neuroscience products.
Bull case: Jazz could leverage its oncology pipeline and acquisitions to offset any oxybate revenue pressure by building new franchises in rare diseases with strong commercial execution.
Bear case: If generics and Lumryz erode the oxybate franchise without sufficient new product success, Jazz's neuroscience revenues could decline sharply and limit overall growth.
Jazz has expanded its rare disease focus with recent acquisitions strengthening the epilepsy pipeline alongside established neuroscience products and new oncology assets. Commercial execution has driven solid revenue growth, but the planned retirement of the chief commercial officer by mid-2027 creates a leadership transition. Will the incoming leader sustain the current go-to-market momentum across franchises or introduce shifts that reshape how new therapies reach patients?
Join the discussion →

Compare Jazz Pharmaceuticals PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 566 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside +61.7% · Top 25%
Profitability
Return on equity (12 months) 22.1% · Top 25%
Return on assets −3.1% · Above median
Net margin (12 months) 20.5% · Top 25%
Operating margin (12 months) 26.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 15.5% · Above median
Balance sheet
Debt / equity 1.00× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 67.3× · Priciest 25%
P/B 3.65× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 3.43× · Cheaper than median
Price / free cash flow 13.8× · Cheapest 25%
EV/EBITDA 9.7× · Cheapest 25%
PEG 0.96× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)78 · sector 0
PAST (return on equity)88 · sector 0
HEALTH (low debt)50 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $902.90 $1,275 +41% vs JAZZ
Vertex Pharmaceuticals Incorporated VRTX $542.50 $608.47 +12% vs JAZZ
Genmab A/S GMAB kr 3,635 kr 4,068 +12% vs JAZZ
WuXi Biologics (Cayman) Inc 2269 HK$48.68 HK$53.55 +10% vs JAZZ
Samsung Biologics Co 207940 1,520,000 KRW 1,644,500 KRW +8% vs JAZZ
argenx SE ARGX $894.77 $908.40 +2% vs JAZZ
CSL Limited CSL A$202.04 A$180.38 −11% vs JAZZ
BeOne Medicines AG 6160 HK$248.60 HK$153.56 −38% vs JAZZ
Celltrion, Inc 068270 215,000 KRW 74,945 KRW −65% vs JAZZ
Royalty Pharma plc RPRX $67.57 $19.01 −72% vs JAZZ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jazz Pharmaceuticals PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jazz Pharmaceuticals PLC Fair Value". https://www.fairvalue-calculator.com/stock/JAZZ

Frequently asked questions

Is Jazz Pharmaceuticals PLC (JAZZ) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $367.54 versus a price of $227.32, about +62% upside (undervalued).
What is the fair value of JAZZ?
Our model-based fair value for Jazz Pharmaceuticals PLC is $367.54 (as of Nov 3, 2026), built from audited fundamentals. The current price: $227.32.
What is the quality score of JAZZ?
Jazz Pharmaceuticals PLC has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jazz Pharmaceuticals PLC (JAZZ)?
Our model-based price target is the fair value of $367.54 (as of Nov 3, 2026) from 13 valuation models. Cautious scenario $178.25, optimistic scenario $656.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Jazz Pharmaceuticals PLC stock forecast for 2026?
Our models put fair value at $367.54, about +62% upside versus a price of $227.32 (undervalued). Cautious scenario $178.25, optimistic scenario $656.64. The calculation is refreshed regularly with new filings.
What is the revenue of Jazz Pharmaceuticals PLC (JAZZ)?
Jazz Pharmaceuticals PLC reported trailing-twelve-month revenue of about $4.6B (latest available figure, as of Nov 3, 2026).
What growth is priced into Jazz Pharmaceuticals PLC (JAZZ)?
For today's price to be fair in a discounted-cash-flow model, Jazz Pharmaceuticals PLC would have to grow free cash flow by +1.5 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.5 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of JAZZ use?
Our models discount Jazz Pharmaceuticals PLC at 8.1 %: a base by market capitalisation (large), damped by beta 0.37, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jazz Pharmaceuticals PLC that is +1.5 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Jazz Pharmaceuticals PLC (JAZZ) delivered so far?
Over the past 5 years revenue at Jazz Pharmaceuticals PLC grew +12.5 % a year. The price currently implies +1.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jazz Pharmaceuticals PLC (JAZZ) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Jazz Pharmaceuticals PLC (+1.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jazz Pharmaceuticals PLC (JAZZ)?
The free-cash-flow yield on the price is 7.26 %: that much free cash flow Jazz Pharmaceuticals PLC produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jazz Pharmaceuticals PLC (JAZZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jazz Pharmaceuticals PLC it is $367.54 per share (as of Nov 3, 2026), against a price of $227.32. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Jazz Pharmaceuticals PLC stock overvalued or undervalued in 2026?
As of Nov 3, 2026, JAZZ trades below its calculated fair value: price $227.32, fair value $367.54, a gap of about +62% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JAZZ?
No. The price is what the market pays today ($227.32); the fair value is what the company's own numbers justify ($367.54). For Jazz Pharmaceuticals PLC the two are $140.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jazz Pharmaceuticals PLC worth?
The market values Jazz Pharmaceuticals PLC at about $15.8B (market capitalisation, as of Nov 3, 2026). Per share that is $227.32; our models calculate a fair value of $367.54 per share.
What do the bullish and bearish scenarios say about JAZZ?
Our models span a range for Jazz Pharmaceuticals PLC: cautious scenario $178.25, base $367.54, optimistic $656.64 per share (as of Nov 3, 2026, price $227.32). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JAZZ?
Jazz Pharmaceuticals PLC trades at a price-to-earnings ratio of 67.3 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $367.54 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2016 to 2024), reported earnings: 17.0. Other multiples: PEG 1.0, P/B 3.7, P/S 3.4, EV/EBITDA 9.7.
What is the PEG ratio of JAZZ?
The PEG ratio of Jazz Pharmaceuticals PLC is 0.96 (P/E divided by earnings growth, as of Nov 3, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Jazz Pharmaceuticals PLC (JAZZ)?
Balance-sheet figures for Jazz Pharmaceuticals PLC (as of Nov 3, 2026): return on equity 22.1%, debt of 1.00 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is JAZZ from its 52-week high?
Jazz Pharmaceuticals PLC trades at $227.32, about 13% below its 52-week high of $261.62 and 73% above the low of $131.16 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $367.54 is for.
Which stocks are comparable to Jazz Pharmaceuticals PLC?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jazz Pharmaceuticals PLC stock attractive at the current price?
The data as of Nov 3, 2026: price $227.32, calculated fair value $367.54 (+62%), Quality Score 53/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JAZZ calculated?
We run Jazz Pharmaceuticals PLC through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $367.54, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Jazz Pharmaceuticals PLC currently trades 38% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jazz Pharmaceuticals PLC (JAZZ)?
The closing price on Nov 5, 2026 was $227.32. Our model-based fair value is $367.54, about +62% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jazz Pharmaceuticals PLC right now?
The model range is unusually wide ($178.25 to $656.64). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Jazz Pharmaceuticals PLC

How large is the market capitalisation of Jazz Pharmaceuticals PLC (JAZZ)?
The market capitalisation of Jazz Pharmaceuticals PLC is $15.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jazz Pharmaceuticals PLC (JAZZ)?
The price-to-sales ratio of Jazz Pharmaceuticals PLC is 3.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jazz Pharmaceuticals PLC (JAZZ)?
Earnings per share at Jazz Pharmaceuticals PLC are $3.38 (price ÷ EPS = P/E 67.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Jazz Pharmaceuticals PLC (JAZZ)?
The net margin of Jazz Pharmaceuticals PLC is −8.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jazz Pharmaceuticals PLC (JAZZ)?
The return on equity (ROE) of Jazz Pharmaceuticals PLC is 22.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jazz Pharmaceuticals PLC (JAZZ)?
On an EBIT basis the return on assets of Jazz Pharmaceuticals PLC is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jazz Pharmaceuticals PLC (JAZZ)?
The operating margin of Jazz Pharmaceuticals PLC is 26.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jazz Pharmaceuticals PLC (JAZZ)?
Revenue at Jazz Pharmaceuticals PLC is growing +15.5% versus a year earlier (3y avg +5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jazz Pharmaceuticals PLC (JAZZ)?
Earnings per share at Jazz Pharmaceuticals PLC are growing +3.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jazz Pharmaceuticals PLC (JAZZ) carry?
The net debt of Jazz Pharmaceuticals PLC is $4.0B (fiscal year 2025, ≈ 3.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jazz Pharmaceuticals PLC in the live analysis

One click puts Jazz Pharmaceuticals PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.